A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Asunaprevir (Primary) ; CC 31244 (Primary) ; Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms YANGTZE
- 22 Jan 2019 According to a Cocrystal Pharma media release, this study is expected to commence in Q1 2019.
- 03 Jan 2019 Status changed from planning to not yet recruiting.
- 15 Oct 2018 New trial record